Henningham Anna, Barnett Timothy C, Maamary Peter G, Walker Mark J
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, University of Queensland, St. Lucia, Queensland 4072, Australia.
Discov Med. 2012 May;13(72):329-42.
Group A Streptococcus (GAS; Streptococcus pyogenes) is a human pathogen which causes significant morbidity and mortality globally. GAS typically infects the throat and skin of the host, causing mild infections such as pharyngitis and impetigo, in addition to life threatening conditions including necrotizing fasciitis, streptococcal toxic shock syndrome (STSS), and bacteremia. Repeated infection with GAS may result in the non-suppurative sequelae, acute rheumatic fever, and acute glomerulonephritis. GAS remains sensitive to the antibiotic penicillin which can be administered as a means to treat infection or as prophylaxis. However, issues with patient compliance and a growing concern over the possible emergence of resistant GAS strains may limit the usefulness of antibiotics in the future. A vaccine capable of preventing GAS infection may be the only effective way to control and eliminate GAS infection and disease.
A组链球菌(GAS;化脓性链球菌)是一种人类病原体,在全球范围内导致显著的发病率和死亡率。GAS通常感染宿主的咽喉和皮肤,除了包括坏死性筋膜炎、链球菌中毒性休克综合征(STSS)和菌血症等危及生命的病症外,还会引起咽炎和脓疱病等轻度感染。反复感染GAS可能导致非化脓性后遗症、急性风湿热和急性肾小球肾炎。GAS对可作为治疗感染手段或预防用药的抗生素青霉素仍敏感。然而,患者依从性问题以及对耐药GAS菌株可能出现的日益担忧,可能会限制抗生素在未来的效用。一种能够预防GAS感染的疫苗可能是控制和消除GAS感染及疾病的唯一有效方法。